drugset / Trial / NCT05421065

Psilocybin-Assisted vs Ketamine-Assisted Psychotherapy for Alcohol Use Disorder

NCT05421065

Phase 2 Active not recruiting 20 enrolled Peggy C Nopoulos
RandomizedParallel-groupOpen-labelBasic science

Summary

This pilot study will collect preliminary data that measures the effects of psilocybin-assisted psychotherapy vs ketamine-assisted psychotherapy on patients struggling with alcohol use.

Timeline

Start
2024-02-02
Primary completion
2025-08-30
Completion
2026-09

Drugs

EvaluationDrugModalityDoseRoute
Comparator Ketamine Small molecule 200 mg Oral
Subject Psilocybin Other / unclassified 25 mg Oral